By downregulating Wnt-driven immunosuppression—which is known to exclude T-cells from the tumor microenvironment—TNIK inhibitors may sensitize “cold” TNBC tumors to anti-PD-1 therapies [104], positioning TNIK as a dual-purpose target for eradicating stemness and enhancing immunity. The gene discussed is TNIK; the disease is neoplasm.